Technical analysis of Solid Biosciences Inc. (SLDB): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Solid Biosciences Inc. is an American biotechnology firm dedicated to creating therapeutic solutions for Duchenne Muscular Dystrophy (DMD). Its most advanced experimental drug, SGT-001, is a gene transfer treatment currently in Phase I/II clinical trials, designed to encourage the production of functional dystrophin protein in patients' muscles. The company is also progressing with SGT-003, which represents a next-generation gene transfer therapy intended for DMD.
Price Performance
| 1 month | -5.45% |
| 3 months | +3.06% |
| Year-to-date | +52.22% |
| 1 year | +56.95% |
| 3 years | +186.17% |
| 5 years | -79.56% |
52-Week Range
| 52-week High | $11.45 |
| 52-week Low | $3.79 |
| Avg Volume (90d) | 1.4M |
Technical Indicators
| SMA 50 | $9.12 |
| SMA 200 | $7.46 |
| Beta | 2.58 |
| 30-day Volatility (annualised) | 55.2% |
| Price vs SMA 50 | -5.9% |
| Price vs SMA 200 | +15.1% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $5.39 | |
| 2025-11 | $5.43 | +0.7% |
| 2025-12 | $5.64 | +3.9% |
| 2026-01 | $6.46 | +14.5% |
| 2026-02 | $6.21 | -3.9% |
| 2026-03 | $7.20 | +15.9% |
| 2026-04 | $7.26 | +0.8% |
| 2026-05 | $7.34 | +1.1% |
| 2026-06 | $9.99 | +36.1% |
| 2026-07 | $8.06 | -19.3% |
| 2026-08 | $9.58 | +18.9% |
| 2026-09 | $8.59 | -10.4% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | | |
| 2026-09-14 | | |
| 2026-09-14 | | |
| 2026-09-14 | | $898M |
| 2026-09-14 | $0.03 | $1M |
| 2026-09-14 | | |
Price
| Price | $8.72 |
| Market Cap | $858M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 3.35 |
| EV / EBITDA | -4.09 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.05 |
| Current Ratio | 13.82 |